CriteriaCaixa: A New Era for Startup Investment in Science and Technology
Introduction to CriteriaCaixa
Based in Barcelona, CriteriaCaixa is the holding company that manages the business assets of the ‘la Caixa’ Banking Foundation. Recently, it has announced an exciting reboot of its startup investment business, aiming to foster the growth of high-potential emerging companies in the realms of science and technology. This strategic move is set to enhance its investment portfolio and contribute positively to society.
Investment Focus and Strategy
CriteriaCaixa plans to allocate €300 million (approximately $343 million) through its two specialized funds: Criteria Bio Ventures and Criteria Venture Tech. The primary focus will be on early-stage companies, particularly in Spain and Portugal, with selective investments across Europe and North America. Notably, nearly 70% of the current portfolio’s value is concentrated in Spain, highlighting the company’s commitment to nurturing local talent and innovation.
The funds are designed to “promote transformative therapies and technologies that can have a positive impact on society, prioritizing long-term value creation.” This mission aligns with the growing demand for innovative solutions in healthcare and technology, especially in light of recent global challenges.
Market Context and Opportunities
The timing of CriteriaCaixa’s €300 million investment comes amid a surge in funding within the targeted sectors. According to EU-Startups’ 2026 coverage, approximately €321.5 million has been disclosed in financing for selected companies in BioTech, clinical-trial technology, cybersecurity, AI infrastructure, and semiconductor industries. Spanish startups alone accounted for around €198.3 million of this funding, showcasing a vibrant ecosystem ripe for investment.
Prominent companies such as Biorce, Gate2Brain, and NeuralTrust are leading the charge in Barcelona, each securing significant funding to advance their innovative solutions. This trend underscores the potential for CriteriaCaixa to make impactful investments that not only yield financial returns but also contribute to societal well-being.
CriteriaCaixa’s Asset Management Approach
As the exclusive independent body managing the assets of the ‘la Caixa’ Foundation, CriteriaCaixa plays a crucial role in ensuring the effective management of its €45 billion gross asset value (GAV). This value is managed through four distinct portfolios: the founding stake in CaixaBank, a significant investments portfolio featuring listed companies like Naturgy and Telefónica, an alternative investments portfolio, and a liquidity portfolio.
The foundation’s investment vehicle aims to generate resources that guarantee its annual budget while increasing assets under management (AUM). This dual focus on financial sustainability and social impact is a hallmark of CriteriaCaixa’s operational philosophy.
Rebranding and Strategic Alignment
In line with its 2030 Strategic Plan, CriteriaCaixa has decided to rebrand its venture capital management company to better reflect its current positioning. Originally founded in 2002 as Caixa Capital Risc, it became a wholly-owned subsidiary of CriteriaCaixa in 2013. The rebranding to Criteria Capital Risc aims to reinforce its market positioning as the venture capital investment arm of CriteriaCaixa.
Investment Vehicles: Criteria Bio Ventures and Criteria Venture Tech
Through its two specialized funds, Criteria Bio Ventures and Criteria Venture Tech, Criteria Capital Risc actively manages its investments, often taking seats on the boards of its portfolio companies.
Criteria Bio Ventures
Criteria Bio Ventures focuses on BioTech and health, seeking to identify, fund, and support innovative companies that are developing new therapies capable of transforming disease management. The fund is particularly interested in entrepreneurs who are working on disruptive therapeutic approaches to address unmet medical needs.
Among its portfolio companies are:
- Minoryx Therapeutics: Developing therapies for rare diseases like adrenoleukodystrophy and Rett syndrome.
- Adaptam Therapeutics: Specializing in immuno-oncology.
- Aboleris Pharma: Targeting autoimmune diseases such as rheumatoid arthritis.
- NRG Therapeutics: Focused on therapies for neurodegenerative diseases like ALS and Parkinson’s.
- Tolerance Bio: Working on therapies to reverse the aging of the immune system.
- Cytospire: Another player in the immuno-oncology space.
Criteria Venture Tech
On the technology side, Criteria Venture Tech specializes in DeepTech and key vertical markets, including AI, cybersecurity, and software and data infrastructures. The fund invests in early-stage technology startups, often assuming lead or co-lead positions, and has the capacity to support high-performing companies even as they grow.
Current portfolio companies include:
- Ipronics: Innovating programmable photonic chips for AI applications.
- Immfly: A digital platform enhancing on-board retail and entertainment experiences.
- KD: Developing chips for advanced optical connectivity.
- Barbara: Offering industrial software solutions for IoT.
Conclusion
CriteriaCaixa’s renewed focus on startup investments in science and technology marks a significant step forward in its mission to foster innovation and societal impact. By strategically allocating resources to promising companies, it aims to not only generate financial returns but also contribute to the advancement of transformative therapies and technologies that can positively impact society. As the landscape of investment continues to evolve, CriteriaCaixa is poised to play a pivotal role in shaping the future of the startup ecosystem in Spain and beyond.
